Xtl Biopharmaceuticals Stock Fundamentals
| XTLB Stock | ILS 4.80 0.40 7.69% |
XTL Biopharmaceuticals fundamentals help investors to digest information that contributes to XTL Biopharmaceutica's financial success or failures. It also enables traders to predict the movement of XTL Stock. The fundamental analysis module provides a way to measure XTL Biopharmaceutica's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to XTL Biopharmaceutica stock.
XTL |
XTL Biopharmaceuticals Company Price To Earning Analysis
XTL Biopharmaceutica's Price to Earnings ratio is typically used for current valuation of a company and is one of the most popular ratios that investors monitor daily. Holding a low PE stock is less risky because when a company's profitability falls, it is likely that earnings will also go down as well. In other words, if you start from a lower position, your downside risk is limited. There are also some investors who believe that low Price to Earnings ratio reflects the low pricing because a given company is in trouble. On the other hand, a higher PE ratio means that investors are paying more for each unit of profit.
Current XTL Biopharmaceutica Price To Earning | 558.33 X |
Most of XTL Biopharmaceutica's fundamental indicators, such as Price To Earning, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, XTL Biopharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Generally speaking, the Price to Earnings ratio gives investors an idea of what the market is willing to pay for the company's current earnings.
| Competition |
Based on the latest financial disclosure, XTL Biopharmaceuticals has a Price To Earning of 558 times. This is much higher than that of the sector and significantly higher than that of the Price To Earning industry. The price to earning for all Israel stocks is notably lower than that of the firm.
XTL Biopharmaceuticals Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining XTL Biopharmaceutica's current stock value. Our valuation model uses many indicators to compare XTL Biopharmaceutica value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across XTL Biopharmaceutica competition to find correlations between indicators driving XTL Biopharmaceutica's intrinsic value. More Info.XTL Biopharmaceuticals is rated first in return on equity category among its peers. It is rated fourth in return on asset category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value XTL Biopharmaceutica by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for XTL Biopharmaceutica's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.XTL Price To Earning Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses XTL Biopharmaceutica's direct or indirect competition against its Price To Earning to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of XTL Biopharmaceutica could also be used in its relative valuation, which is a method of valuing XTL Biopharmaceutica by comparing valuation metrics of similar companies.XTL Biopharmaceutica is currently under evaluation in price to earning category among its peers.
XTL Fundamentals
| Return On Equity | 0.38 | |||
| Return On Asset | -0.1 | |||
| Current Valuation | 61.84 M | |||
| Shares Outstanding | 514.21 M | |||
| Shares Owned By Insiders | 16.20 % | |||
| Price To Earning | 558.33 X | |||
| EBITDA | (940 K) | |||
| Net Income | 435 K | |||
| Cash And Equivalents | 5.06 M | |||
| Cash Per Share | 0.01 X | |||
| Current Ratio | 51.07 X | |||
| Book Value Per Share | 0.01 X | |||
| Cash Flow From Operations | (1.05 M) | |||
| Beta | 1.03 | |||
| Market Capitalization | 236.53 K |
About XTL Biopharmaceutica Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze XTL Biopharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of XTL Biopharmaceutica using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of XTL Biopharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases. XTL Biopharmaceuticals Ltd. was founded in 1993 and is headquartered in Ramat Gan, Israel. XTL BIOPHARMACEUTI is traded on Tel Aviv Stock Exchange in Israel.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in XTL Stock
XTL Biopharmaceutica financial ratios help investors to determine whether XTL Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in XTL with respect to the benefits of owning XTL Biopharmaceutica security.